Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of ARGX-119 in Healthy Participants
NCT05670704Phase 1Completed
- Sponsor
- argenx
- Start
- Feb 2023
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in congenital myasthenic syndromes (CMS) and amyotrophic lateral sclerosis (ALS) comparing ARGX-119 with Placebo (2 arms). Primary endpoint: Number of treatment-emergent adverse events up to 157 days. Started Feb 2023; status: completed.
02
Drugs
adimanebart
03
Conditions
congenital myasthenic syndromes (CMS)amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT05670704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05670704.